20 Result(s)

Article

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia

D C de Leeuw, H J M P Verhagen, F Denkers, F G Kavelaars, P J M Valk… in Leukemia (2016)

Article

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

As relapses are common in acute myeloid leukemia (AML), early relapse prediction is of high importance. Although conventional minimal residual disease (MRD) measurement is carried out in bone marrow (BM), peri...

W Zeijlemaker, A Kelder, Y J M Oussoren-Brockhoff, W J Scholten, A N Snel… in Leukemia (2016)

Article

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia

Relapses after initial successful treatment in acute myeloid leukemia are thought to originate from the outgrowth of leukemic stem cells. Their flow cytometrically assessed frequency is of importance for relap...

W Zeijlemaker, A Kelder, Y J M Oussoren-Brockhoff, W J Scholten, A N Snel… in Leukemia (2016)

Article

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

The majority of pediatric and younger adult (<60 years) AML patients achieve complete remission. However, 30–40% of patients relapse and display a dismal outcome. Recently we described a frequent instability o...

C Bachas, G J Schuurhuis, Y G Assaraf, Z J Kwidama, A Kelder, F Wouters… in Leukemia (2012)

Article

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

Insensitivity of chronic myeloid leukemia (CML) hematopoietic stem cells to tyrosine kinase inhibitors (TKIs) prevents eradication of the disease and may be involved in clinical resistance. For improved treatm...

J J W M Janssen, W Deenik, K G M Smolders, B J van Kuijk, W Pouwels, A Kelder… in Leukemia (2012)

Article

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenoty** in 94 children with AML enrol...

V H J van der Velden, A van der Sluijs-Geling, B E S Gibson, J G te Marvelde… in Leukemia (2010)

Article

Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38− population survives chemotherapy an...

A van Rhenen, B Moshaver, A Kelder, N Feller, A W M Nieuwint, S Zweegman… in Leukemia (2007)

Article

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in p...

J Cloos, B F Goemans, C J Hess, J W van Oostveen, Q Waisfisz, S Corthals… in Leukemia (2006)

Article

Identification of genes potentially involved in disease transformation of CML

In patients with chronic myeloid leukemia (CML) who do not reach a (near) complete cytogenetic response, the disease progresses over several years from an indolent, chronic phase into a rapidly fatal blast cri...

J J W M Janssen, S M Klaver, Q Waisfisz, G Pasterkamp, D P V de Kleijn… in Leukemia (2005)

Article

Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method

In acute myeloid leukaemia (AML), alterations in apoptotic pathways are crucial for treatment outcome, resulting either in refractoriness or in minimal residual disease (MRD). The apoptosis characteristics of ...

C J Hess, F Denkers, G J Ossenkoppele, Q Waisfisz, C J McElgunn, E Eldering… in Leukemia (2004)

Article

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

Outgrowth of minimal residual disease (MRD) in acute myeloid leukaemia (AML) is responsible for the occurrence of relapses. MRD can be quantified by immunophenoty** on a flow cytometer using the expression o...

N Feller, M A van der Pol, A van Stijn, G W D Weijers, A H Westra, B W Evertse… in Leukemia (2004)

Article

Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene

J J W M Janssen, A Hochhaus, J W van Oostveen, Q Waisfisz, G J Schuurhuis… in Leukemia (2004)

Article

Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile

A van Stijn, A Kok, M A van Stalborch, M A van der Pol, N Feller, A H Westra… in Leukemia (2004)

Article

Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis

M A van der Pol, N Feller, G J Ossenkoppele, G W D Weijers, A H Westra… in Leukemia (2003)

Article

Multiparameter flow cytometric quantification of apoptosis-related protein expression

A van Stijn, A Kok, M A van der Pol, N Feller, G M J M Roemen, A H Westra… in Leukemia (2003)

Article

A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia

Minimal residual disease (MRD) cells are thought to be responsible for the persistence and relapse of acute myeloid leukemia (AML). Flow cytometric MRD detection by the establishment of a leukemia-associated p...

A van Stijn, A Kok, M A van der Pol, N Feller, G M J M Roemen, A H Westra… in Leukemia (2003)

Article

High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome

In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P =...

N Feller, G J Schuurhuis, M A van der Pol, G Westra, G W D Weijers, A van Stijn… in Leukemia (2003)

Article

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

Bridget T. Hill, L. K. Hosking, S. McClean… in Journal of Cancer Research and Clinical On… (1991)